CRD007 for the Treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and Symptomatic Carriers | DuchenneXchange

welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!
rareClinical
completed

CRD007 for the Treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and Symptomatic Carriers

key information

study id #: NCT01540604

condition: Duchenne Muscular Dystrophy , Becker Muscular Dystrophy

status: completed

purpose:

This is an investigation of the efficacy and safety of CRD007 in Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD) and symptomatic carriers.

intervention: CRD007

mechanism of action: Non-steroidal agent to decrease inflammation

results: https://clinicaltrials.gov/ct2/show/results/NCT01540604

last updated: November 22, 2018

study details

phase of development: Phase 2

inclusion criteria:
Documented diagnosis of dystrophinopathy

exclusion criteria:
Severe functional impairment

study contacts

sponsor: RSPR Pharma AB

investigators: T Sejersen, MD PhD

locations: Sweden

rareRelated